Holen Sie sich die Stockscreener-App
2.77
5.96%
-0.08
Schlusskurs vom Vortag:
$2.85
Offen:
$2.66
24-Stunden-Volumen:
6,149
Relative Volume:
0.01
Marktkapitalisierung:
$357.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.86M
KGV:
-0.1725
EPS:
-16.054
Netto-Cashflow:
$-17.68M
1W Leistung:
-10.67%
1M Leistung:
-26.78%
6M Leistung:
-0.37%
1J Leistung:
-75.88%
1-Tages-Spanne:
$2.6311
$2.75
1-Wochen-Bereich:
$2.61
$3.21
52-Wochen-Spanne:
$0.92
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Firmenname
Indaptus Therapeutics Inc
Sektor
Branche
Telefon
(646) 427-2727
Adresse
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.68 | 399.73M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
519.88 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
661.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.55 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.88 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.82 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Indaptus Therapeutics (INDP) News Flow - Moomoo
Indaptus Therapeutics Company Profile & Introduction - Moomoo
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan
Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused - Stock Titan
Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
INDAPTUS THERAPEUTICSTO ISSUE 20 MLN SHARES AT $0.6 PER SHARESEC FILING - Moomoo
Indaptus TherapeuticsTo Issue 20 Million Shares At $0.6 Per ShareSEC Filing - TradingView
Indaptus Therapeutics Announces Private Placement of Common Stock - TipRanks
Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement - Stock Titan
Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share - TradingView
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form PRE 14A Sunshine Biopharma Inc For: 22 June By Investing.com - Investing.com Australia
Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan - Stock Titan
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
Indaptus Therapeutics Inc (INDP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Top Cue Biopharma (CUE) Competitors 2026 - MarketBeat
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders - Caledonian Record
Indaptus Therapeutics, Inc. announced that it expects to receive $12 million in funding - marketscreener.com
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com
12 Health Care Stocks Moving In Thursday's Intraday SessionAdial Pharmaceuticals (NASDAQ:ADIL), Aditxt - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks
Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
INDPIndaptus Therapeutics Inc Stock Price and Quote - Finviz
INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com
Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli
Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):